Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Undervalued Narrative

Simply Wall St.02-12

AdvertisementWhy Supernus Pharmaceuticals (SUPN) Is On Investors’ Radar Today Supernus Pharmaceuticals (SUPN) has drawn fresh attention after recent share performance data showed a roughly flat move ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611897566?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-02-12 23:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611897566","market":"sg","top_or_hot":-1,"title":"Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Undervalued Narrative","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Supernus Pharmaceuticals (SUPN) Is On Investors’ Radar Today Supernus Pharmaceuticals (SUPN) has drawn fresh attention after recent share performance data showed a roughly flat move ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/assessing-supernus-pharmaceuticals-supn-valuation-after-rece\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Undervalued Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Undervalued Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-12 23:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/assessing-supernus-pharmaceuticals-supn-valuation-after-rece><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Supernus Pharmaceuticals (SUPN) Is On Investors’ Radar Today Supernus Pharmaceuticals (SUPN) has drawn fresh attention after recent share performance data showed a roughly flat move ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/assessing-supernus-pharmaceuticals-supn-valuation-after-rece\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/assessing-supernus-pharmaceuticals-supn-valuation-after-rece","article_id":"2611897566","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/assessing-supernus-pharmaceuticals-supn-valuation-after-rece","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611897566","pubTimestamp":1770910749,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Supernus Pharmaceuticals (SUPN) Is On Investors’ Radar Today\nSupernus Pharmaceuticals (SUPN) has drawn fresh attention after recent share performance data showed a roughly flat move over the past month, alongside gains over the past 3 months and year.\nSee our latest analysis for Supernus Pharmaceuticals.\nThe recent 7 day share price return of 4.6% and 90 day share price return of 15.53% suggest momentum has been building, while the 1 year total shareholder return of 31.67% points to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals","BK4007":"制药"},"translate_title":"在最近的股价势头和低估叙述之后评估Supernus Pharmaceuticals(SUPN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1.5},"content_text":"AdvertisementWhy Supernus Pharmaceuticals (SUPN) Is On Investors’ Radar Today Supernus Pharmaceuticals (SUPN) has drawn fresh attention after recent share performance data showed a roughly flat move over the past month, alongside gains over the past 3 months and year. See our latest analysis for Supernus Pharmaceuticals. The recent 7 day share price return of 4.6% and 90 day share price return of 15.53% suggest momentum has been building, while the 1 year total shareholder return of 31.67% points to stronger gains for longer term holders. If this kind of sustained move in healthcare catches your interest, it could be a good moment to see what else is lining up in our screen of 25 healthcare AI stocks. With Supernus posting solid multi period returns, annual revenue growth of 13.78% and a reported loss of US$19.12 million, plus a roughly 19% gap to the average analyst target, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth? Most Popular Narrative: 16.3% Undervalued Based on the most followed valuation narrative, Supernus Pharmaceuticals' fair value of $61.33 sits above the last close of $51.34. This raises some clear questions about what is built into that number.  Growth driven by expanding CNS patient pool, innovative product launches, and pipeline advancements supports higher revenue, margin expansion, and robust market positioning. Strong balance sheet and targeted acquisitions enable portfolio diversification, providing flexibility for inorganic growth and increased long-term shareholder value.  Read the complete narrative. Want to see what is sitting behind that fair value gap? The narrative leans heavily on revenue momentum, margin shifts, and a future profit multiple that is anything but ordinary. Result: Fair Value of $61.33 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, rising SG&A and R&D costs, along with reliance on a few key CNS products, mean any sales disappointment or pipeline setback could quickly challenge that undervalued case. Find out about the key risks to this Supernus Pharmaceuticals narrative.  Build Your Own Supernus Pharmaceuticals Narrative If you see the numbers differently or simply want to test your own view against the data, you can build a personal thesis in just a few minutes: Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Supernus Pharmaceuticals. Looking for more investment ideas? If you are weighing what to do next after looking at Supernus, this is the moment to broaden your watchlist with a few focused, data backed ideas.  Target reliable income by scanning 13 dividend fortresses that could help anchor your portfolio with steady cash returns. Hunt for potential mispricings with 51 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them. Protect your downside by reviewing 85 resilient stocks with low risk scores that score well on financial strength and volatility checks.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611897566","isCrawlerRequest":true}